Effects of zoledronic acid and ibandronic acid on renal functions and calcium, phosphorus and alkaline phosphatase levels in breast cancer patients with bone metastases: a retrospective analysis

Creative Commons License

Fidan E., Yildiz B., Kavgaci H., Ozdemir F., Aydin F.

WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, cilt.16, ss.176-178, 2012 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 16
  • Basım Tarihi: 2012
  • Doi Numarası: 10.5114/wo.2012.28799
  • Dergi Adı: WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.176-178
  • Eskişehir Osmangazi Üniversitesi Adresli: Hayır

Özet

Aim of the study: Bone is a common site of metastasis in patients with breast cancer. Skeletal complications associated with bone metastasis are commonly treated with bisphosphonates. However, there are a number of side-effects associated with these, such as renal failure, hypocalcemia and osteonecrosis of the jaw. We aimed to determine the effects of ibandronic and zoledronic acid on serum creatinine (SCr), calcium (Ca), phosphorus (P), alkaline phosphatase (ALP) and estimated glomerular filtration rates (eGFR). The objective was to determine the safety of these bisphosphonates, especially zoledronic acid.